Doxazosin treatment in cocaine use disorder: pharmacogenetic response based on an alpha-1 adrenoreceptor subtype D genetic variant

References

• Stankowski RV, Kloner RA, Rezkalla SH. Cardiovascular consequences of cocaine use. Trends Cardiovasc Med. 2015;25:517–26.doi:10.1016/j.tcm.2014.12.013.
   PubMed Web of Science ®Google Scholar
• Czoty PW, Stoops WW, Rush CR. Evaluation of the “Pipeline” for development of medications for cocaine use disorder: a review of translational preclinical, human laboratory, and clinical trial research. Pharmacol Rev. 2016;68:533–62.doi:10.1124/pr.115.011668.
   PubMed Web of Science ®Google Scholar
• Mark GP, Shabani S, Dobbs LK, Hansen ST. Cholinergic modulation of mesolimbic dopamine function and reward. Physiol Behav. 2011;104:76–81.doi:10.1016/j.physbeh.2011.04.052.
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang GJ, Fowler JS, Tomasi D, Telang F. Addiction: beyond dopamine reward circuitry. Proc Natl Acad Sci USA. 2011;108:15037–42.doi:10.1073/pnas.1010654108.
   PubMed Web of Science ®Google Scholar
• Havranek MM, Hulka LM, Tasiudi E, Eisenegger C, Vonmoos M, Preller KH, Mossner R, Baumgartner MR, Seifritz E, Grunblatt E, et al. alpha2A -Adrenergic receptor polymorphisms and mRNA expression levels are associated with delay discounting in cocaine users. Addict Biol. 2017;22:561–69. doi:10.1111/adb.12324.
   PubMed Web of Science ®Google Scholar
• Shorter D, Lindsay JA, Kosten TR. The alpha-1 adrenergic antagonist doxazosin for treatment of cocaine dependence: a pilot study. Drug Alcohol Depend. 2013;131:66–70.doi:10.1016/j.drugalcdep.2012.11.021.
   PubMed Web of Science ®Google Scholar
• Shorter D, Nielsen DA, Hamon SC, Nielsen EM, Kosten TR, Newton TF, De La Garza R 2nd. The alpha-1 adrenoceptor (ADRA1A) genotype moderates the magnitude of acute cocaine-induced subjective effects in cocaine-dependent individuals. Pharmacogenet Genomics. 2016;26:428–35.doi:10.1097/FPC.0000000000000234.
   PubMed Web of Science ®Google Scholar
• Zhang XY, Kosten TA. Prazosin, an alpha-1 adrenergic antagonist, reduces cocaine-induced reinstatement of drug-seeking. Biol Psychiatry. 2005;57:1202–04.doi:10.1016/j.biopsych.2005.02.003.
   PubMed Web of Science ®Google Scholar
• Paladini CA, Mitchell JM, Williams JT, Mark GP. Cocaine self-administration selectively decreases noradrenergic regulation of metabotropic glutamate receptor-mediated inhibition in dopamine neurons. J Neurosci. 2004;24:5209–15.doi:10.1523/JNEUROSCI.1079-04.2004.
   PubMed Web of Science ®Google Scholar
• Blanc PD, Saxena M, Olson KR. Drug detection and trauma cause–a case control study of fatal injuries. J Toxicol Clin Toxicol. 1994;32:137–45.doi:10.3109/15563659409000443.
   PubMed Web of Science ®Google Scholar
• Grenhoff J, Nisell M, Ferre S, Aston-Jones G, Svensson TH. Noradrenergic modulation of midbrain dopamine cell firing elicited by stimulation of the locus coeruleus in the rat. J Neural Transm Gen Sect. 1993;93:11–25.doi:10.1007/BF01244934.
   PubMed Web of Science ®Google Scholar
• Schmidt KT, Weinshenker D. Adrenaline rush: the role of adrenergic receptors in stimulant-induced behaviors. Mol Pharmacol. 2014;85:640–50.doi:10.1124/mol.113.090118.
   PubMed Web of Science ®Google Scholar
• Newton TF, De La Garza R 2nd, Brown G, Kosten TR, Mahoney JJ 3rd, Haile CN. Noradrenergic alpha(1) receptor antagonist treatment attenuates positive subjective effects of cocaine in humans: a randomized trial. PLoS One. 2012;7:e30854.doi:10.1371/journal.pone.0030854.
   PubMed Web of Science ®Google Scholar
• Zhang X, Nielsen DA, Domingo CB, Shorter DI, Nielsen EM, Kosten TR. Pharmacogenetics of dopamine beta-hydroxylase in cocaine dependence therapy with doxazosin. Addict Biol. 2019;24:531–38. doi:10.1111/adb.12611.
   Web of Science ®Google Scholar
• Unnerstall JR, Fernandez I, Orensanz LM. The alpha-adrenergic receptor: radiohistochemical analysis of functional characteristics and biochemical differences. Pharmacol Biochem Behav. 1985;22:859–74.doi:10.1016/0091-3057(85)90538-6.
   PubMed Web of Science ®Google Scholar
• Perez DM, Doze VA. Cardiac and neuroprotection regulated by alpha(1)-adrenergic receptor subtypes. J Recept Signal Transduct Res. 2011;31:98–110.doi:10.3109/10799893.2010.550008.
   PubMed Web of Science ®Google Scholar
• Ahles A, Engelhardt S. Polymorphic variants of adrenoceptors: pharmacology, physiology, and role in disease. Pharmacol Rev. 2014;66:598–637.doi:10.1124/pr.113.008219.
   PubMed Web of Science ®Google Scholar
• Rokosh DG, Simpson PC. Knockout of the alpha 1A/C-adrenergic receptor subtype: the alpha 1A/C is expressed in resistance arteries and is required to maintain arterial blood pressure. Proc Natl Acad Sci USA. 2002;99:9474–79.doi:10.1073/pnas.132552699.
   PubMed Web of Science ®Google Scholar
• Cavalli A, Lattion AL, Hummler E, Nenniger M, Pedrazzini T, Aubert JF, Michel MC, Yang M, Lembo G, Vecchione C, et al. Decreased blood pressure response in mice deficient of the alpha1b-adrenergic receptor. Proc Natl Acad Sci USA. 1997;94:11589–94.doi:10.1073/pnas.94.21.11589.
   PubMed Web of Science ®Google Scholar
• Perez DM, Piascik MT, Graham RM. Solution-phase library screening for the identification of rare clones: isolation of an alpha 1D-adrenergic receptor cDNA. Mol Pharmacol. 1991;40:876–83.
   PubMed Web of Science ®Google Scholar
• Lomasney JW, Cotecchia S, Lorenz W, Leung WY, Schwinn DA, Yang-Feng TL, Brownstein M, Lefkowitz RJ, Caron MG. Molecular cloning and expression of the cDNA for the alpha 1A-adrenergic receptor. The gene for which is located on human chromosome 5. J Biol Chem. 1991;266:6365–69.
   PubMed Web of Science ®Google Scholar
• Tanoue A, Nasa Y, Koshimizu T, Shinoura H, Oshikawa S, Kawai T, Sunada S, Takeo S, Tsujimoto G. The alpha(1D)-adrenergic receptor directly regulates arterial blood pressure via vasoconstriction. J Clin Invest. 2002;109:765–75.doi:10.1172/JCI200214001.
   PubMed Web of Science ®Google Scholar
• Sadalge A, Coughlin L, Fu H, Wang B, Valladares O, Valentino R, Blendy JA. Alpha 1d Adrenoceptor signaling is required for stimulus induced locomotor activity. Mol Psychiatry. 2003;8:664–72.doi:10.1038/sj.mp.4001351.
   PubMed Web of Science ®Google Scholar
• Mishima K, Tanoue A, Tsuda M, Hasebe N, Fukue Y, Egashira N, Takano Y, Kamiya HO, Tsujimoto G, Iwasaki K, et al. Characteristics of behavioral abnormalities in alpha1d-adrenoceptors deficient mice. Behav Brain Res. 2004;152:365–73.doi:10.1016/j.bbr.2003.10.038.
   PubMed Web of Science ®Google Scholar
• Bexis S, Docherty JR. Role of alpha1-adrenoceptor subtypes in the effects of methylenedioxy methamphetamine (MDMA) on body temperature in the mouse. Br J Pharmacol. 2008;153:591–97.doi:10.1038/sj.bjp.0707590.
   PubMed Web of Science ®Google Scholar
• Kikuchi-Utsumi K, Ishizaka M, Matsumura N, Watabe M, Aoyama K, Sasakawa N, Nakaki T. Involvement of the alpha(1D)-adrenergic receptor in methamphetamine-induced hyperthermia and neurotoxicity in rats. Neurotox Res. 2013;24:130–38.doi:10.1007/s12640-012-9369-9.
   PubMed Web of Science ®Google Scholar
• Drouin C, Blanc G, Villegier AS, Glowinski J, Tassin JP. Critical role of alpha1-adrenergic receptors in acute and sensitized locomotor effects of D-amphetamine, cocaine, and GBR 12783: influence of preexposure conditions and pharmacological characteristics. Synapse. 2002;43:51–61.doi:10.1002/syn.10023.
   PubMed Web of Science ®Google Scholar
• Shorter D, Nielsen DA, Huang W, Harding MJ, Hamon SC, Kosten TR. Pharmacogenetic randomized trial for cocaine abuse: disulfiram and alpha1A-adrenoceptor gene variation. Eur Neuropsychopharmacol. 2013;23:1401–07.doi:10.1016/j.euroneuro.2013.05.014.
   PubMed Web of Science ®Google Scholar
• Compton WM, Dawson DA, Goldstein RB, Grant BF. Crosswalk between DSM-IV dependence and DSM-5 substance use disorders for opioids, cannabis, cocaine and alcohol. Drug Alcohol Depend. 2013;132:387–90.doi:10.1016/j.drugalcdep.2013.02.036.
   PubMed Web of Science ®Google Scholar
• Johnson TM 2nd, Burrows PK, Kusek JW, Nyberg LM, Tenover JL, Lepor H, Roehrborn CG. Medical therapy of prostatic symptoms research G. The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia. J Urol. 2007;178:2045–50. discussion 2050-2041. doi:10.1016/j.juro.2007.07.013.
   PubMed Web of Science ®Google Scholar
• Kampman KM, Volpicelli JR, McGinnis DE, Alterman AI, Weinrieb RM, D’Angelo L, Epperson LE. Reliability and validity of the cocaine selective severity assessment. Addict Behav. 1998;23:449–61.doi:10.1016/S0306-4603(98)00011-2.
   PubMed Web of Science ®Google Scholar
• Mulvaney FD, Alterman AI, Boardman CR, Kampman K. Cocaine abstinence symptomatology and treatment attrition. J Subst Abuse Treat. 1999;16:129–35.doi:10.1016/S0740-5472(98)00017-8.
   PubMed Web of Science ®Google Scholar
• Kosten TR, Wu G, Huang W, Harding MJ, Hamon SC, Lappalainen J, Nielsen DA. Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine beta-hydroxylase. Biol Psychiatry. 2013;73:219–24.doi:10.1016/j.biopsych.2012.07.011.
   PubMed Web of Science ®Google Scholar
• Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, Haussler D. The human genome browser at UCSC. Genome Res. 2002;12:996–1006.doi:10.1101/gr.229102.
   PubMed Web of Science ®Google Scholar
• Nielsen DA, Harding MJ, Hamon S, Huang W, Kosten T. Modifying role of serotonergic 5-HTTLPR & TPH2 variants on disulfiram treatment of cocaine addiction: a preliminary study. Genes Brain Behavior. 2012;2012 Aug 23. [Epub ahead of print]. doi:10.1111/j.1601-183X.2012.00839.x.
   PubMed Web of Science ®Google Scholar
• Kosten T, Wu G, Huang W, Harding M, Hamon S, Lappalainen J, Neilsen D. Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine beta-hydroxylase. Biol Psychiatry. 2012; 2012 Aug 17. Epub ahead of print. doi:10.1016/s0002-9378(16)33297-5.
   Web of Science ®Google Scholar
• Lao O, van Duijn K, Kersbergen P, de Knijff P, Kayser M. Proportioning whole-genome single-nucleotide-polymorphism diversity for the identification of geographic population structure and genetic ancestry. Am J Hum Genet. 2006;78:680–90.doi:10.1086/501531.
   PubMed Web of Science ®Google Scholar
• Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: L. Erlbaum Associates; 1988.
   Google Scholar
• Hubisz MJ, Falush D, Stephens M, Pritchard JK. Inferring weak population structure with the assistance of sample group information. Mol Ecol Resour. 2009;9:1322–32.doi:10.1111/j.1755-0998.2009.02591.x.
   PubMed Web of Science ®Google Scholar
• Pritchard JK, Stephens M, Rosenberg NA, Donnelly P. Association mapping in structured populations. Am J Hum Genet. 2000;67:170–81.doi:10.1086/302959.
   PubMed Web of Science ®Google Scholar
• Nonen S, Okamoto H, Fujio Y, Takemoto Y, Yoshiyama M, Hamaguchi T, Matsui Y, Yoshikawa J, Kitabatake A, Azuma J. Polymorphisms of norepinephrine transporter and adrenergic receptor alpha1D are associated with the response to beta-blockers in dilated cardiomyopathy. Pharmacogenomics J. 2008;8:78–84.doi:10.1038/sj.tpj.6500450.
   PubMed Web of Science ®Google Scholar
• Parkman HP, Jacobs MR, Mishra A, Hurdle JA, Sachdeva P, Gaughan JP, Krynetskiy E. Domperidone treatment for gastroparesis: demographic and pharmacogenetic characterization of clinical efficacy and side-effects. Dig Dis Sci. 2011;56:115–24.doi:10.1007/s10620-010-1472-2.
   PubMed Web of Science ®Google Scholar
• Parkman HP, Mishra A, Jacobs M, Pathikonda M, Sachdeva P, Gaughan J, Krynetskiy E. Clinical response and side effects of metoclopramide: associations with clinical, demographic, and pharmacogenetic parameters. J Clin Gastroenterol. 2012;46:494–503.doi:10.1097/MCG.0b013e3182522624.
   PubMed Web of Science ®Google Scholar
• Merriman JD, Aouizerat BE, Cataldo JK, Dunn LB, Kober K, Langford DJ, West C, Cooper BA, Paul SM, Miaskowski C. Associations between catecholaminergic, GABAergic, and serotonergic genes and self-reported attentional function in oncology patients and their family caregivers. Eur J Oncol Nurs. 2015;19:251–59.doi:10.1016/j.ejon.2014.11.004.
   PubMed Web of Science ®Google Scholar
• Yang M, Verfurth F, Buscher R, Michel MC. Is alpha1D-adrenoceptor protein detectable in rat tissues? Naunyn Schmiedebergs Arch Pharmacol. 1997;355:438–46.doi:10.1007/PL00004966.
   PubMed Web of Science ®Google Scholar
• Nagaoka Y, Ahmed M, Hossain M, Bhuiyan MA, Ishiguro M, Nakamura T, Watanabe M, Nagatomo T. Amino acids of the human alpha1d-adrenergic receptor involved in antagonist binding. J Pharmacol Sci. 2008;106:114–20.doi:10.1254/jphs.FP0071412.
   PubMed Web of Science ®Google Scholar
• Johnson JA, Liggett SB. Cardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future directions. Clin Pharmacol Ther. 2011;89:366–78.doi:10.1038/clpt.2010.315.
   PubMed Web of Science ®Google Scholar
• Tanoue A, Koshimizu TA, Tsujimoto G. Transgenic studies of alpha(1)-adrenergic receptor subtype function. Life Sci. 2002;71:2207–15.doi:10.1016/S0024-3205(02)02012-X.
   PubMed Web of Science ®Google Scholar